Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
BEDMINSTER, N.J., and DUBLIN, Ireland, June 01, 2017 -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2017 Global Healthcare Conference in New York City on Thursday, June 8, 2017, at 10:30 a.m. ET.
A live audio webcast of the presentation will be available at: http://wsw.com/webcast/jeff105/amrn, and will be accessible at the same link for 30 days.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Availability of other Information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information Investor Relations: Elisabeth Schwartz Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315 [email protected] Lee M. Stern Trout Group In U.S.: +1 (646) 378-2992 [email protected] Media Inquiries: Ovidio Torres Finn Partners In U.S.: +1 (312) 329 3911 [email protected]
